RxDoctor Payments Data

Doug Kim, MD

Family Medicine · Federal Way, WANPI 1720087067

Payments from drug & device makers

$8,912in general payments, 2019–2025

Across 368 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Amgen$595
  • Boehringer Ingelheim$578
  • AstraZeneca$529
  • Novo Nordisk$484
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,70798%
  • Education$2052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,912 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$54,708
Medicare patients
110
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlyxambiEmpagliflozin/Linagliptin111$152,940
JardianceEmpagliflozin66$77,640
XareltoRivaroxaban71$72,403
OzempicSemaglutide38$61,371
CreonLipase/Protease/Amylase47$56,635
VascepaIcosapent Ethyl90$53,364
Tresiba Flextouch U-100Insulin Degludec46$47,208
LinzessLinaclotide42$36,006
EliquisApixaban26$29,345
MyrbetriqMirabegron29$28,364
TradjentaLinagliptin21$23,435
SymbicortBudesonide/Formoterol Fumarate45$17,131
Omega-3 Acid Ethyl Esters215$14,835
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,878
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide267$6,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimGlyxambi, Jardiance, Tradjenta$578$254,014198 claims
AbbVieCreon, Linzess, Restasis$1,258$98,179100 claims
Johnson & JohnsonXarelto$422$72,40371 claims
Novo NordiskOzempic$484$61,37138 claims
PfizerEliquis$121$29,34526 claims
Astellas Pharma US IncMyrbetriq$319$28,36429 claims
AstraZenecaSymbicort$529$17,13145 claims
GSKTrelegy Ellipta$173$6,87811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Federal Way

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →